Anti-Fibroblast Activation Protein immunotherapy to treat pancreatic ductal adenocarcinoma

• Unité de recherche: INNOSUISSE
• Numéro de projet: 17994.1 PFLS-LS
• Titre du projet anglais: Anti-Fibroblast Activation Protein immunotherapy to treat pancreatic ductal adenocarcinoma

Description succincte (Allemand)

Anti-Fibroblast Activation Protein immunotherapy to treat pancreatic ductal adenocarcinoma

Description succincte (Anglais)

Anti-Fibroblast Activation Protein immunotherapy to treat pancreatic ductal adenocarcinoma

Résumé des résultats (Abstract) (Allemand)

More than 300¿000 patients are diagnosed with pancreatic ductal adenocarcinoma (PDA) each year with a median survival of only 2-17 months. 82C2 is a novel human derived monoclonal antibody with proven efficacy in mouse carcinoma models, with potential to prolong survival for PDA patients with improved efficacy compared to current standard of care. This CTI project application seeks support to advance 82C2 into clinical trials to treat PDA patients by 2019.

Résumé des résultats (Abstract) (Anglais)

More than 300¿000 patients are diagnosed with pancreatic ductal adenocarcinoma (PDA) each year with a median survival of only 2-17 months. 82C2 is a novel human derived monoclonal antibody with proven efficacy in mouse carcinoma models, with potential to prolong survival for PDA patients with improved efficacy compared to current standard of care. This CTI project application seeks support to advance 82C2 into clinical trials to treat PDA patients by 2019.